Medindia LOGIN REGISTER
Medindia
Advertisement

Presentation of North America's First Certificate for BS 25999, the New Standard for Business Continuity

Wednesday, July 9, 2008 General News
Advertisement
RESTON, Va., July 8 BSI announced today that RepligenCorporation, Waltham, MA (Nasdaq: RGEN); the world's leading supplier ofrecombinant Protein A, a consumable used in the manufacture of monoclonalantibodies, the fastest growing segment of the biopharmaceutical industry hasachieved BS 25999 certification. Repligen is the first company in NorthAmerica to have achieved certification for their commitment to ensuringbusiness continuity in the event of disaster or disruption.
Advertisement

BS 25999 is a visionary standard designed to keep your business goingduring the most challenging and unexpected circumstances. It provides a basisfor understanding, developing, implementing and managing business continuitywithin your organization and gives you confidence when dealing withstakeholders both within and outside your organization. BS 25999 is anauditable standard which means that through certification, you have aframework for continual improvement and the ability to demonstrate to yourstakeholders that your BCM program meets globally accepted best practice.
Advertisement

"By earning BS 25999 certification, Repligen is clearly demonstratingtheir commitment to ensure continued operation in the face of any potentialcause of business disruption," said Gary Pearsons, President of BSI ManagementSystems. "Repligen is the first company in North America to achieve BS 25999certification. This is just one more example of the leadership role Repligenhas earned in their industry. Through the combined strength of Repligenimplementing a disciplined management system and BSI providing independentverification and certification; Repligen's stakeholders and customers can beassured of the resiliency of their operations."

"Repligen is at the head of a long and growing list of leading-edgecompanies wishing to prove that they are doing what is required to protecttheir businesses, their stakeholders, and their customers," Pearsons added.

"As the world's leading supplier of recombinant Protein A, we felt that itwas important to be on the cutting edge of business continuity to ensure anuninterrupted supply of products to our customers and ultimately to patients,"stated Walter C. Herlihy, President and Chief Executive Officer of RepligenCorporation. "Implementation of and certification to BS 25999 has helpedRepligen become more resilient, and agile by providing valuable insight intothe issues and challenges that we may face in the event of a businessinterruption. We are very proud to be the first company in North America tohave gained certification."

BSI Management Systems is one of the world's largest certification bodies,with over 60,000 certified locations and clients in more than 100 countries.Operating through a global network, BSI Management Systems providesassessment, certification and training services in all critical areas ofmanagement disciplines including:

About Repligen and Recombinant Protein A

Repligen is the world's leading supplier of recombinant Protein A, aconsumable used in the manufacture of monoclonal antibodies. There areapproximately 20 monoclonal antibodies that have received regulatory approvalwith more than 200 products in various stages of clinical development. Theworldwide revenues from this class of drug exceeded $20 billion in 2006 andare forecast to exceed $30 billion in 2010. Monoclonal antibodies are thelargest and fastest growing class of drug in the biopharmaceutical industry.(http://www.repligen.com)Media information Shereen Abuzobaa VP Marketing BSI Management Systems Email: [email protected] Website: http://www.bsiamerica.com About BSI Management Systems

SOURCE BSI Management Systems
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close